medac is breaking new ground and cooperating with Scienta Lab, an innovative AI company based in France. Thanks to its unique and proprietary AI technology, Scienta Lab leverages multimodal data to support a better understanding of immuno-inflammatory diseases and their variability at the patient level. With this collaboration, medac aims at gaining a better understanding of patients' daily therapy routine.
Image: Medac
medac is breaking new ground and cooperating with Scienta Lab, an innovative AI company based in France. Thanks to its unique and proprietary AI technology, Scienta Lab leverages multimodal data to support a better understanding of immuno-inflammatory diseases and their variability at the patient level. With this collaboration, medac aims at gaining a better understanding of patients’ daily therapy routine.
The use of artificial intelligence (AI) is also being intensively discussed in rheumatology. medac has already underlined its commitment to new ideas and digital solutions by initiating the Ekipa Challenge “Innovate Rheumatology”. As part of this challenge, the company deepened the contact with Scienta Lab, a French company with expertise in AI and immunology. Both companies have now concluded a cooperation agreement.
The aim is to gain more information about patients’ everyday therapy lives
In the context of this collaboration, Scienta Lab will apply its proprietary technology on real world data to extract medical concepts and identify new patterns. This research work will give medac the opportunity to gain more insights into the everyday therapy of patients with rheumatological diseases.
“We are very pleased about the opportunity to find out more about the therapy situation of our patients with rheumatological diseases” explained Heiner Will, Managing Director at medac GmbH. “With the new insights, we hope to better understand the patients’ situation so that we can better respond to their needs.” continued Will.
“We are pleased to collaborate with medac, an independent group developing medicinal treatments. This partnership demonstrates the commitment of medac to support a personalized therapy journey in rheumatology thanks to innovative solutions. Since its creation, Scienta Lab has been focused on pioneering the AI-powered Precision Immunology revolution, and we are pleased to join forces with medac in the pursuit of this goal.” explained Camille Bouget, CEO & co-founder of Scienta Lab.
Source: Company Press Release